PDCD1 and gastric carcinoma: Notably, PNR was also a strong prognostic biomarker for PFS and overall survival after anti‐PD‐1 combination therapy in patients with solid tumors, such as biliary tract carcinoma, gastric carcinoma, or colon cancer.